Ptom Keith Roach News Today

BEVESPI AEROSPHERE (glycopyrronium bromide/formoterol fumarate) accepted for use in NHS Scotland for adult patients with chronic pulmonary respiratory disease (COPD) BY THE SCOTTISH MEDICINES CONSORTIUM (SMC) ·       Bevespi is a fixed dose combination of glycopyrronium brom...

PATIENTS IN SCOTLAND WITH AN ADVANCED FORM OF PROSTATE CANCER CAN NOW ACCESS LYNPARZA (OLAPARIB) WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE WITHOUT A BIOMARKER TEST

Read comments made by former RCN president Dame Anne Marie Rafferty during a panel session on fixing the "broken" NHS culture.

Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) has been recommended by the National Institute for Health and Care Excellence (NICE) for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1Durvalumab is AstraZeneca UK&rsq...

Lynparza (olaparib) receives a positive recommendation from NICE for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive high-grade ovarian, fallopian tube or peritoneal cancer. Following today’s decision from the National Institute for Health and Care Excellence (NICE) to recommend Lynparza ...

Therapy treats patients with specific types of ovarian, fallopian tube or primary peritoneal cancer - News - PharmaTimes

In final draft guidance, NICE has recommended dapagliflozin (Forxiga) for patients with heart failure regardless of ejection fraction.

With visions of the UK as a ‘life sciences superpower’ at risk, we report from Great Ormond Street hospital on what’s being done to give children access to new drugs

Decision will create opportunity for therapy to be used earlier in the treatment pathway - News - PharmaTimes

The Scottish Medicines Consortium has accepted fam-trastuzumab deruxtecan-nxki as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have received 1 prior anti–HER2-based therapy.